CNBX Pharmaceuticals is developing a platform that leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies tailored to each patients specific profile. By developing tools to assess effectiveness on a personalized basis, Cannabics seeks to make cannabinoids part of the future of cancer therapy. CNBX Pharmaceuticals operates In Israel as G.R.I.N Ultra Ltd where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.